RecruitingPhase 3NCT07776210
Rare condition
Graft versus host disease
205
studies recruiting now
as of 7 Sept 2026
1,695
studies registered in total
as of 7 Sept 2026
13
countries with a recruiting site
as of 7 Sept 2026
20 Aug 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNot applicableNCT02592291
Mobile Health Self-Management and Support System for Chronic and Complex Health Conditions
RecruitingPhase 1 / Phase 2NCT05531786
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
RecruitingPhase 2NCT07249346
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RecruitingPhase 2NCT07354074
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 205 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Graft versus host disease study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Graft versus host disease
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
7 approved treatments and 80 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Tacrolimus (Adoport)Approved: Muromonab-Cd3 (Orthoclone okt3)Approved: BelumosudilApproved: Belumosudil Mesylate (Rezurock)Approved: Allogeneic T Cells Genetically Modified With A Retroviral Vector Encoding For A Truncated Form Of The Human Low Affinity Nerve Growth Factor Receptor (Deltalngfr) And The Herpes Simplex I Virus Thymidine Kinase (Hsv-Tk Mut2) (Zalmoxis)Approved: Ruxolitinib Phosphate (Jakafi)Approved: Cyclosporine (Capimune)
Phase 3Imatinib
Phase 3Begelomab (Begedina)
Phase 3Itacitinib
Phase 3Tacrolimus Anhydrous
Phase 3Cyclophosphamide (Cyclophosphamide)
Phase 3Daclizumab (Zenapax)
Phase 3Rituximab (Blitzima)
Phase 3Remestemcel-L (Prochymal)
+ 72 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).